Single	O
-	X
dose	X
oral	O
nap	O
##ro	X
##xen	X
for	O
acute	O
post	O
##oper	X
##ative	X
pain	O
:	O
a	O
quantitative	O
systematic	O
review	O
Background	O
Na	O
##p	X
##ro	X
##xen	X
and	O
nap	O
##ro	X
##xen	X
sodium	O
are	O
non	O
-	X
s	X
##tero	X
##idal	X
anti	O
-	X
inflammatory	X
drugs	O
used	O
in	O
a	O
variety	O
of	O
painful	O
conditions	O
,	O
including	O
the	O
treatment	O
of	O
post	O
##oper	X
##ative	X
pain	O
.	O

This	O
review	O
aims	O
to	O
assess	O
the	O
efficacy	O
,	O
safety	O
and	O
duration	O
of	O
action	O
of	O
a	O
single	O
oral	O
dose	O
of	O
nap	O
##ro	X
##xen	X
/	X
nap	X
##ro	X
##xen	X
sodium	O
for	O
moderate	O
to	O
severe	O
acute	O
post	O
##oper	X
##ative	X
pain	O
in	O
adults	O
,	O
compared	O
with	O
place	O
##bo	X
.	O

Method	O
##s	X
The	O
Cochrane	O
Library	O
(	O
issue	O
4	O
2002	O
)	O
,	O
E	O
##MB	X
##AS	X
##E	X
,	O
Pub	O
##M	X
##ed	X
,	O
ME	O
##D	X
##L	X
##IN	X
##E	X
and	O
an	O
in	O
-	X
house	X
database	O
were	O
searched	O
for	O
random	O
##ised	X
,	O
double	O
blind	O
,	O
place	O
##bo	X
controlled	O
trials	O
of	O
a	O
single	O
dose	O
of	O
oral	O
##ly	X
administered	O
nap	O
##ro	X
##xen	X
or	O
nap	O
##ro	X
##xen	X
sodium	O
in	O
adults	O
with	O
acute	O
post	O
##oper	X
##ative	X
pain	O
.	O

Pain	O
relief	O
or	O
pain	O
intensity	O
data	O
were	O
extracted	O
and	O
converted	O
into	O
di	O
##cho	X
##tom	X
##ous	X
information	O
to	O
give	O
the	O
number	O
of	O
patients	B-species
with	O
at	O
least	O
50	O
%	O
pain	O
relief	O
over	O
4	O
to	O
6	O
hours	O
.	O

Re	O
##lative	X
benefit	O
and	O
number	O
-	X
needed	X
-	X
to	X
-	X
treat	X
were	O
then	O
calculated	O
.	O

The	O
percentage	O
of	O
patients	B-species
with	O
any	O
adverse	O
event	O
,	O
number	O
-	X
needed	X
-	X
to	X
-	X
harm	X
,	O
and	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
were	O
also	O
calculated	O
.	O

Results	O
Ten	O
trials	O
with	O
99	O
##6	X
patients	B-species
in	O
met	O
the	O
inclusion	O
criteria	O
.	O

Six	O
trials	O
compared	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
(	O
252	O
patients	B-species
)	O
with	O
place	O
##bo	X
(	O
248	O
patients	B-species
)	O
;	O
the	O
N	O
##NT	X
for	O
at	O
least	O
50	O
%	O
pain	O
relief	O
over	O
six	O
hours	O
was	O
2	O
.	X
6	X
(	O
95	O
%	O
confidence	O
interval	O
2	O
.	X
2	X
to	O
3	O
.	X
2	X
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
number	O
of	O
patients	B-species
experiencing	O
any	O
adverse	O
event	O
on	O
treatment	O
compared	O
with	O
place	O
##bo	X
.	O

Weight	O
##ed	X
mean	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
was	O
7	O
.	X
6	X
hours	O
for	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
(	O
206	O
patients	B-species
)	O
and	O
2	O
.	X
6	X
hours	O
for	O
place	O
##bo	X
(	O
205	O
patients	B-species
)	O
.	O

Four	O
other	O
trials	O
used	O
lower	O
doses	O
.	O

Con	O
##c	X
##lusion	X
A	O
single	O
oral	O
dose	O
of	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
is	O
an	O
effective	O
anal	O
##ges	X
##ic	X
in	O
the	O
treatment	O
of	O
acute	O
post	O
##oper	X
##ative	X
pain	O
.	O

A	O
low	O
incidence	O
of	O
adverse	O
events	O
was	O
found	O
,	O
although	O
these	O
were	O
not	O
reported	O
consistently	O
.	O

Background	O
Na	O
##p	X
##ro	X
##xen	X
and	O
nap	O
##ro	X
##xen	X
sodium	O
are	O
non	O
-	X
s	X
##tero	X
##idal	X
anti	O
-	X
inflammatory	X
drugs	O
(	O
NSA	O
##ID	X
##s	X
)	O
that	O
in	O
##hibit	X
pro	O
##sta	X
##g	X
##land	X
##in	X
synthesis	O
[	O
1	O
]	O
.	O

Na	O
##p	X
##ro	X
##xen	X
is	O
a	O
derivative	O
of	O
prop	O
##ion	X
##ic	X
acid	O
and	O
nap	O
##ro	X
##xen	X
sodium	O
is	O
the	O
sodium	O
salt	O
.	O

Na	O
##p	X
##ro	X
##xen	X
sodium	O
550	O
mg	O
is	O
equivalent	O
to	O
500	O
mg	O
of	O
nap	O
##ro	X
##xen	X
[	O
2	O
]	O
.	O

Na	O
##p	X
##ro	X
##xen	X
is	O
clinical	O
##ly	X
effective	O
in	O
patients	B-species
with	O
post	O
##oper	X
##ative	X
pain	O
[	O
3	O
]	O
.	O

The	O
post	O
##oper	X
##ative	X
pain	O
period	O
is	O
often	O
dominated	O
by	O
the	O
need	O
to	O
find	O
effective	O
ways	O
of	O
blocking	O
the	O
inflammatory	O
reaction	O
and	O
re	O
##lie	X
##ving	X
pain	O
[	O
4	O
]	O
.	O

In	O
one	O
US	O
study	O
,	O
posts	O
##urg	X
##ical	X
pain	O
was	O
the	O
leading	O
cause	O
of	O
concern	O
in	O
57	O
%	O
of	O
patients	B-species
before	O
surgery	O
[	O
5	O
]	O
.	O

This	O
concern	O
is	O
not	O
mi	O
##sp	X
##laced	X
.	O

A	O
survey	O
of	O
3000	O
newly	O
discharged	O
patients	B-species
(	O
surgical	O
and	O
medical	O
)	O
in	O
UK	O
hospitals	O
showed	O
that	O
87	O
%	O
had	O
moderate	O
to	O
severe	O
pain	O
in	O
hospital	O
,	O
and	O
33	O
%	O
had	O
pain	O
that	O
was	O
present	O
all	O
or	O
most	O
of	O
the	O
time	O
[	O
6	O
]	O
.	O

A	O
recent	O
,	O
extensive	O
review	O
of	O
post	O
##oper	X
##ative	X
pain	O
management	O
found	O
that	O
severe	O
pain	O
,	O
and	O
poor	O
or	O
fair	O
pain	O
relief	O
,	O
was	O
experienced	O
by	O
almost	O
one	O
in	O
five	O
hospital	O
patients	B-species
[	O
7	O
]	O
.	O

S	O
##pecific	X
data	O
for	O
the	O
frequency	O
of	O
nap	O
##ro	X
##xen	X
administration	O
in	O
post	O
##oper	X
##ative	X
pain	O
are	O
unavailable	O
.	O

However	O
in	O
England	O
in	O
2002	O
there	O
were	O
over	O
1	O
.	X
2	X
million	O
prescription	O
##s	X
for	O
oral	O
nap	O
##ro	X
##xen	X
and	O
nap	O
##ro	X
##xen	X
sodium	O
in	O
primary	O
care	O
[	O
8	O
]	O
.	O

The	O
recommended	O
daily	O
dose	O
of	O
nap	O
##ro	X
##xen	X
is	O
500	O
mg	O
or	O
1000	O
mg	O
[	O
9	O
]	O
.	O

The	O
use	O
of	O
conventional	O
NSA	O
##ID	X
##s	X
has	O
been	O
associated	O
with	O
upper	O
gas	O
##tro	X
##int	X
##est	X
##inal	X
bleeding	O
and	O
per	O
##fo	X
##ration	X
,	O
acute	B-disease
liver	I-disease
injury	I-disease
,	O
acute	B-disease
re	I-disease
##nal	X
injury	I-disease
,	O
and	O
heart	B-disease
failure	I-disease
[	O
10	O
]	O
.	O

Co	O
##mp	X
##lication	X
##s	X
are	O
more	O
likely	O
to	O
occur	O
with	O
chronic	O
use	O
and	O
NSA	O
##ID	X
##s	X
generally	O
present	O
fewer	O
risks	O
if	O
used	O
short	O
term	O
[	O
11	O
]	O
.	O

There	O
is	O
some	O
evidence	O
that	O
nap	O
##ro	X
##xen	X
may	O
reduce	O
the	O
risk	O
of	O
acute	B-disease
my	I-disease
##oc	X
##ard	X
##ial	X
in	I-disease
##far	X
##ction	X
[	O
12	O
-	X
14	X
]	O
.	O

E	O
##st	X
##imate	X
##s	X
of	O
relative	O
benefit	O
and	O
N	O
##NT	X
(	O
number	O
-	X
needed	X
-	X
to	X
-	X
treat	X
)	O
can	O
be	O
derived	O
from	O
pain	O
data	O
[	O
15	O
]	O
.	O

The	O
N	O
##NT	X
is	O
the	O
number	O
of	O
patients	B-species
that	O
need	O
to	O
be	O
treated	O
for	O
one	O
patient	B-species
to	O
benefit	O
from	O
the	O
active	O
treatment	O
who	O
would	O
not	O
have	O
benefited	O
from	O
place	O
##bo	X
.	O

N	O
##NT	X
##s	X
allows	O
indirect	O
comparisons	O
of	O
different	O
anal	O
##ges	X
##ics	X
by	O
looking	O
at	O
relative	O
efficacy	O
,	O
which	O
are	O
usually	O
just	O
as	O
good	O
as	O
direct	O
comparisons	O
between	O
different	O
interventions	O
[	O
16	O
]	O
.	O

Met	O
##a	X
-	X
analysis	X
of	O
individual	O
trials	O
is	O
useful	O
because	O
it	O
can	O
help	O
to	O
reduce	O
the	O
effect	O
that	O
chance	O
plays	O
on	O
the	O
final	O
result	O
,	O
giving	O
a	O
more	O
precise	O
estimate	O
of	O
drug	O
efficacy	O
than	O
looking	O
at	O
individual	O
clinical	O
trials	O
alone	O
[	O
17	O
,	O
18	O
]	O
.	O

It	O
does	O
this	O
by	O
combining	O
data	O
from	O
trials	O
that	O
are	O
clinical	O
##ly	X
ho	O
##mogeneous	X
,	O
and	O
reach	O
a	O
certain	O
standard	O
of	O
trial	O
design	O
;	O
random	O
##isation	X
,	O
blinding	O
and	O
place	O
##bo	X
control	O
are	O
important	O
factors	O
for	O
reducing	O
bias	O
and	O
chance	O
effects	O
[	O
19	O
]	O
.	O

Inc	O
##lusion	X
of	O
reports	O
of	O
low	O
quality	O
in	O
meta	O
-	X
analysis	X
is	O
likely	O
to	O
give	O
misleading	O
results	O
[	O
20	O
]	O
,	O
and	O
therefore	O
assessments	O
of	O
report	O
quality	O
are	O
important	O
for	O
determining	O
whether	O
trials	O
should	O
be	O
included	O
or	O
excluded	O
.	O

In	O
acute	O
pain	O
trials	O
the	O
outcome	O
most	O
often	O
reported	O
is	O
total	O
pain	O
relief	O
(	O
TO	O
##TP	X
##AR	X
)	O
or	O
sum	O
##med	X
pain	O
intensity	O
difference	O
(	O
SP	O
##ID	X
)	O
over	O
the	O
four	O
to	O
six	O
hours	O
in	O
which	O
the	O
studies	O
are	O
usually	O
conducted	O
.	O

These	O
were	O
therefore	O
the	O
primary	O
outcomes	O
of	O
interest	O
,	O
together	O
with	O
any	O
information	O
on	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
and	O
adverse	O
events	O
,	O
of	O
a	O
single	O
dose	O
of	O
oral	O
nap	O
##ro	X
##xen	X
/	X
nap	X
##ro	X
##xen	X
sodium	O
over	O
4	O
to	O
6	O
hours	O
in	O
the	O
treatment	O
of	O
acute	O
post	O
##oper	X
##ative	X
pain	O
,	O
from	O
meta	O
-	X
analysis	X
of	O
random	O
##ised	X
,	O
double	O
blind	O
,	O
place	O
##bo	X
controlled	O
clinical	O
trials	O
.	O

Method	O
##s	X
Re	O
##lev	X
##ant	X
studies	O
were	O
sought	O
regardless	O
of	O
language	O
,	O
publication	O
type	O
or	O
publication	O
status	O
.	O

The	O
electronic	O
databases	O
used	O
were	O
The	O
Cochrane	O
Library	O
(	O
Issue	O
4	O
2002	O
)	O
,	O
all	O
years	O
and	O
all	O
databases	O
;	O
ME	O
##D	X
##L	X
##IN	X
##E	X
and	O
Pre	O
##M	X
##ed	X
##line	X
,	O
all	O
years	O
from	O
1966	O
to	O
December	O
2002	O
;	O
E	O
##MB	X
##AS	X
##E	X
,	O
all	O
years	O
from	O
1980	O
to	O
December	O
2002	O
and	O
Pub	O
##M	X
##ed	X
,	O
all	O
years	O
from	O
1966	O
to	O
December	O
2002	O
.	O

Since	O
1996	O
hand	O
searching	O
of	O
journals	O
has	O
been	O
undertaken	O
by	O
part	O
of	O
the	O
Cochrane	O
Col	O
##la	X
##bor	X
##ation	X
.	O

An	O
in	O
-	X
house	X
database	O
containing	O
hand	O
searched	O
copies	O
of	O
random	O
##ised	X
controlled	O
trials	O
in	O
pain	O
for	O
the	O
years	O
1954	O
to	O
1995	O
[	O
21	O
]	O
,	O
together	O
with	O
unpublished	O
trials	O
held	O
in	O
-	X
house	X
containing	O
individual	O
patient	B-species
data	O
,	O
were	O
also	O
searched	O
.	O

Reference	O
lists	O
of	O
retrieved	O
articles	O
were	O
searched	O
.	O

A	O
##bs	X
##tracts	X
were	O
not	O
sought	O
.	O

Ph	O
##arma	X
##ce	X
##utical	X
companies	O
were	O
not	O
contacted	O
.	O

The	O
search	O
strategy	O
contained	O
nap	O
##ro	X
##xen	X
and	O
`	O
`	X
nap	O
##ro	X
##xen	X
sodium	O
'	O
'	X
,	O
together	O
with	O
registered	O
brand	O
names	O
[	O
2	O
]	O
.	O

Full	O
details	O
of	O
the	O
search	O
strategy	O
can	O
be	O
found	O
in	O
Additional	O
File	O
1	O
.	O

Po	O
##ten	X
##tial	X
trials	O
were	O
assessed	O
by	O
at	O
least	O
two	O
reviewers	O
from	O
abstract	O
##s	X
retrieved	O
in	O
the	O
search	O
.	O

If	O
insufficient	O
information	O
was	O
given	O
to	O
determine	O
if	O
a	O
trial	O
should	O
be	O
included	O
,	O
or	O
if	O
the	O
abstract	O
was	O
not	O
present	O
,	O
the	O
complete	O
paper	O
was	O
located	O
and	O
assessed	O
.	O

Studies	O
were	O
included	O
if	O
they	O
were	O
random	O
##ised	X
,	O
double	O
blind	O
,	O
place	O
##bo	X
controlled	O
clinical	O
trials	O
in	O
which	O
a	O
single	O
oral	O
dose	O
of	O
nap	O
##ro	X
##xen	X
(	O
or	O
nap	O
##ro	X
##xen	X
sodium	O
)	O
and	O
a	O
matched	O
place	O
##bo	X
were	O
administered	O
to	O
patients	B-species
experiencing	O
moderate	O
to	O
severe	O
base	O
##line	X
pain	O
,	O
following	O
a	O
surgical	O
procedure	O
.	O

Trials	O
had	O
to	O
state	O
patient	B-species
reported	O
pain	O
relief	O
or	O
pain	O
intensity	O
over	O
4	O
to	O
6	O
hours	O
,	O
measured	O
using	O
valid	O
##ated	X
pain	O
scales	O
.	O

These	O
could	O
be	O
either	O
,	O
1	O
.	X
a	O
five	O
-	X
point	X
cat	O
##ego	X
##rical	X
pain	O
relief	O
(	O
PR	O
)	O
scale	O
with	O
standard	O
or	O
comparable	O
word	O
##ing	X
(	O
none	O
,	O
slight	O
,	O
moderate	O
,	O
good	O
,	O
complete	O
)	O
,	O
2	O
.	X
a	O
four	O
-	X
point	X
cat	O
##ego	X
##rical	X
pain	O
intensity	O
(	O
P	O
##I	X
)	O
scale	O
(	O
none	O
,	O
mild	O
,	O
moderate	O
,	O
severe	O
)	O
,	O
3	O
.	X
a	O
10	O
cm	O
visual	O
analogue	O
scale	O
(	O
VA	O
##S	X
)	O
for	O
pain	O
relief	O
or	O
pain	O
intensity	O
.	O

Global	O
evaluation	O
##s	X
of	O
patient	B-species
reported	O
pain	O
relief	O
over	O
4	O
to	O
6	O
hours	O
were	O
also	O
considered	O
acceptable	O
,	O
if	O
measured	O
on	O
a	O
standard	O
five	O
-	X
point	X
scale	O
.	O

For	O
each	O
potentially	O
relevant	O
trial	O
,	O
a	O
quality	O
assessment	O
scale	O
was	O
used	O
to	O
consider	O
if	O
it	O
should	O
be	O
included	O
in	O
the	O
review	O
.	O

This	O
employs	O
a	O
valid	O
##ated	X
three	O
item	O
scale	O
with	O
a	O
maximum	O
quality	O
score	O
of	O
five	O
[	O
22	O
]	O
.	O

A	O
minimum	O
of	O
two	O
points	O
(	O
for	O
random	O
##isation	X
and	O
double	O
blinding	O
)	O
were	O
required	O
for	O
a	O
study	O
to	O
be	O
included	O
.	O

Quality	O
assessments	O
were	O
made	O
independently	O
by	O
at	O
least	O
two	O
reviewers	O
and	O
disputes	O
settled	O
by	O
discussion	O
between	O
all	O
reviewers	O
.	O

The	O
number	O
of	O
patients	B-species
random	O
##ised	X
into	O
each	O
treatment	O
group	O
(	O
intention	O
to	O
treat	O
)	O
was	O
used	O
in	O
the	O
efficacy	O
analysis	O
.	O

Mean	O
TO	O
##TP	X
##AR	X
(	O
total	O
pain	O
relief	O
)	O
or	O
mean	O
SP	O
##ID	X
(	O
sum	O
##med	X
pain	O
intensity	O
difference	O
)	O
over	O
4	O
to	O
6	O
hours	O
were	O
either	O
extracted	O
,	O
or	O
calculated	O
from	O
pain	O
data	O
within	O
each	O
trial	O
.	O

These	O
were	O
converted	O
into	O
%	O
ma	O
##x	X
##TO	X
##TP	X
##AR	X
or	O
%	O
ma	O
##x	X
##SP	X
##ID	X
(	O
the	O
percentage	O
of	O
the	O
maximum	O
possible	O
total	O
pain	O
relief	O
or	O
sum	O
##med	X
pain	O
intensity	O
)	O
,	O
using	O
verified	O
equations	O
[	O
23	O
-	X
26	X
]	O
.	O

These	O
data	O
were	O
used	O
to	O
calculate	O
the	O
number	O
of	O
patients	B-species
in	O
each	O
trial	O
with	O
at	O
least	O
50	O
%	O
pain	O
relief	O
for	O
both	O
active	O
treatment	O
and	O
place	O
##bo	X
.	O

From	O
this	O
,	O
N	O
##NT	X
##s	X
were	O
calculated	O
with	O
95	O
%	O
confidence	O
intervals	O
[	O
27	O
]	O
.	O

Re	O
##lative	X
benefit	O
and	O
relative	O
risk	O
estimates	O
with	O
95	O
%	O
confidence	O
intervals	O
were	O
calculated	O
using	O
the	O
fixed	O
effects	O
model	O
[	O
28	O
]	O
.	O

A	O
statistical	O
##ly	X
significant	O
benefit	O
of	O
the	O
active	O
treatment	O
over	O
place	O
##bo	X
was	O
assumed	O
when	O
the	O
lower	O
limit	O
of	O
the	O
95	O
%	O
confidence	O
interval	O
(	O
C	O
##I	X
)	O
of	O
the	O
relative	O
benefit	O
was	O
greater	O
than	O
one	O
.	O

A	O
statistical	O
##ly	X
significant	O
benefit	O
of	O
place	O
##bo	X
over	O
active	O
treatment	O
was	O
assumed	O
when	O
the	O
upper	O
limit	O
of	O
the	O
95	O
%	O
C	O
##I	X
was	O
less	O
than	O
one	O
.	O

Ho	O
##mo	X
##gene	X
##ity	X
of	O
trials	O
was	O
assessed	O
visually	O
[	O
29	O
]	O
because	O
he	O
##tero	X
##gene	X
##ity	X
tests	O
have	O
been	O
shown	O
to	O
be	O
un	O
##hel	X
##pf	X
##ul	X
[	O
30	O
,	O
31	O
]	O
.	O

Fun	O
##nel	X
plots	O
were	O
not	O
used	O
to	O
assess	O
publication	O
bias	O
as	O
these	O
have	O
also	O
been	O
shown	O
to	O
be	O
un	O
##hel	X
##pf	X
##ul	X
[	O
32	O
,	O
33	O
]	O
.	O

To	O
determine	O
if	O
there	O
was	O
a	O
significant	O
difference	O
between	O
N	O
##NT	X
##s	X
for	O
different	O
doses	O
of	O
active	O
treatment	O
,	O
or	O
between	O
N	O
##NT	X
##s	X
for	O
equivalent	O
doses	O
of	O
nap	O
##ro	X
##xen	X
and	O
nap	O
##ro	X
##xen	X
sodium	O
,	O
the	O
z	O
test	O
[	O
34	O
]	O
was	O
used	O
.	O

Secondary	O
outcomes	O
were	O
extracted	O
in	O
those	O
included	O
papers	O
reporting	O
them	O
.	O

These	O
were	O
(	O
i	O
)	O
number	O
of	O
patients	B-species
re	O
##med	X
##ica	X
##ting	X
following	O
the	O
initial	O
dose	O
,	O
(	O
ii	O
)	O
mean	O
or	O
median	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
,	O
(	O
ii	O
##i	X
)	O
reports	O
of	O
any	O
adverse	O
event	O
,	O
(	O
i	O
##v	X
)	O
reports	O
of	O
particular	O
adverse	O
events	O
such	O
as	O
headache	B-disease
or	O
vomit	O
##ing	X
,	O
and	O
(	O
v	O
)	O
reasons	O
for	O
patient	B-species
disco	O
##ntin	X
##uation	X
or	O
withdrawal	O
.	O

Weight	O
##ed	X
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
was	O
calculated	O
as	O
follows	O
.	O

For	O
each	O
trial	O
,	O
the	O
number	O
of	O
patients	B-species
taking	O
active	O
treatment	O
was	O
multi	O
##plied	X
by	O
the	O
percentage	O
re	O
##med	X
##ica	X
##ting	X
by	O
12	O
hours	O
.	O

These	O
values	O
were	O
sum	O
##med	X
and	O
divided	O
by	O
the	O
total	O
number	O
of	O
patients	B-species
taking	O
active	O
treatment	O
from	O
all	O
trials	O
using	O
re	O
##med	X
##ica	X
##tion	X
as	O
an	O
outcome	O
.	O

Number	O
-	X
needed	X
-	X
to	X
-	X
harm	X
(	O
N	O
##N	X
##H	X
)	O
and	O
relative	O
risk	O
were	O
calculated	O
for	O
the	O
number	O
of	O
patients	B-species
in	O
each	O
treatment	O
group	O
reporting	O
any	O
adverse	O
event	O
,	O
and	O
for	O
specific	O
events	O
such	O
as	O
headache	B-disease
,	O
di	O
##zzi	X
##ness	X
,	O
d	O
##rows	X
##iness	X
etc	O
,	O
in	O
the	O
same	O
way	O
as	O
for	O
N	O
##NT	X
##s	X
.	O

All	O
calculations	O
were	O
performed	O
in	O
Microsoft	O
Ex	O
##cel	X
X	O
for	O
the	O
Macintosh	O
.	O

Q	O
##U	X
##OR	X
##OM	X
guidelines	O
were	O
followed	O
.	O

Results	O
Fifty	O
-	X
nine	X
potential	O
papers	O
were	O
identified	O
from	O
the	O
search	O
.	O

One	O
of	O
these	O
[	O
35	O
]	O
could	O
not	O
be	O
obtained	O
from	O
the	O
British	O
Library	O
.	O

Forty	O
-	X
eight	X
trials	O
were	O
excluded	O
for	O
at	O
least	O
one	O
of	O
the	O
following	O
reasons	O
.	O

Thirty	O
-	X
one	X
did	O
not	O
use	O
place	O
##bo	X
,	O
seven	O
had	O
no	O
4	O
to	O
6	O
hour	O
data	O
,	O
six	O
did	O
not	O
measure	O
base	O
##line	X
pain	O
or	O
did	O
not	O
have	O
moderate	O
to	O
severe	O
base	O
##line	X
pain	O
,	O
six	O
had	O
no	O
extract	O
##able	X
anal	O
##ges	X
##ic	X
efficacy	O
data	O
,	O
six	O
were	O
not	O
double	O
blind	O
,	O
two	O
used	O
inappropriate	O
pain	O
scales	O
and	O
one	O
was	O
not	O
random	O
##ised	X
.	O

Full	O
references	O
and	O
reasons	O
for	O
exclusion	O
can	O
be	O
seen	O
in	O
Additional	O
File	O
2	O
.	O

Ten	O
studies	O
[	O
1	O
,	O
36	O
-	X
42	X
]	O
containing	O
information	O
from	O
a	O
total	O
of	O
99	O
##6	X
patients	B-species
met	O
the	O
selection	O
criteria	O
and	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Two	O
of	O
the	O
included	O
studies	O
were	O
currently	O
unpublished	O
,	O
in	O
which	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
was	O
used	O
as	O
an	O
active	O
com	O
##par	X
##ator	X
in	O
acute	O
dental	O
pain	O
studies	O
of	O
r	O
##of	X
##ec	X
##ox	X
##ib	X
[	O
Me	O
##rc	X
##k	X
Research	O
Laboratories	O
,	O
unpublished	O
studies	O
,	O
1997	O
]	O
.	O

In	O
the	O
10	O
trials	O
58	O
##2	X
patients	B-species
received	O
active	O
treatment	O
(	O
50	O
##5	X
nap	O
##ro	X
##xen	X
sodium	O
)	O
and	O
41	O
##4	X
received	O
place	O
##bo	X
.	O

One	O
paper	O
[	O
41	O
]	O
reported	O
on	O
two	O
trials	O
conducted	O
at	O
two	O
separate	O
hospitals	O
,	O
using	O
two	O
different	O
doses	O
of	O
active	O
treatment	O
,	O
and	O
was	O
the	O
only	O
included	O
study	O
to	O
use	O
nap	O
##ro	X
##xen	X
rather	O
than	O
nap	O
##ro	X
##xen	X
sodium	O
.	O

The	O
results	O
from	O
these	O
two	O
clinical	O
##ly	X
ho	O
##mogeneous	X
trials	O
were	O
combined	O
to	O
give	O
a	O
weighted	O
mean	O
TO	O
##TP	X
##AR	X
for	O
nap	O
##ro	X
##xen	X
200	O
mg	O
(	O
40	O
patients	B-species
)	O
,	O
nap	O
##ro	X
##xen	X
400	O
mg	O
(	O
37	O
patients	B-species
)	O
,	O
and	O
place	O
##bo	X
(	O
40	O
patients	B-species
)	O
,	O
because	O
the	O
number	O
of	O
patients	B-species
at	O
hospital	O
two	O
was	O
very	O
small	O
.	O

All	O
trials	O
had	O
a	O
quality	O
score	O
of	O
three	O
or	O
more	O
,	O
but	O
only	O
one	O
had	O
a	O
maximum	O
score	O
of	O
five	O
[	O
37	O
]	O
.	O

All	O
included	O
studies	O
were	O
of	O
six	O
hours	O
duration	O
or	O
longer	O
.	O

Five	O
trials	O
using	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
provided	O
information	O
on	O
re	O
##med	X
##ica	X
##tion	X
[	O
37	O
,	O
38	O
,	O
42	O
,	O
unpublished	O
studies	O
]	O
.	O

These	O
trials	O
were	O
of	O
12	O
hours	O
duration	O
or	O
longer	O
.	O

The	O
participants	B-species
ranged	O
in	O
age	O
from	O
14	O
to	O
72	O
years	O
old	O
.	O

Six	O
hundred	O
and	O
eighty	O
-	X
two	X
(	O
68	O
%	O
)	O
patients	B-species
underwent	O
dental	O
surgery	O
,	O
the	O
rest	O
either	O
or	O
##th	X
##op	X
##ae	X
##dic	X
or	O
general	O
surgery	O
.	O

Full	O
details	O
of	O
the	O
included	O
studies	O
can	O
be	O
found	O
in	O
Additional	O
File	O
3	O
.	O

E	O
##ff	X
##ici	X
##acy	X
analysis	O
A	O
summary	O
of	O
anal	O
##ges	X
##ic	X
efficacy	O
results	O
for	O
all	O
doses	O
can	O
be	O
seen	O
in	O
Table	O
1	O
.	O

The	O
z	O
test	O
showed	O
no	O
significant	O
difference	O
between	O
the	O
N	O
##NT	X
##s	X
for	O
550	O
mg	O
,	O
400	O
/	X
440	X
mg	O
and	O
200	O
/	X
220	X
mg	O
doses	O
of	O
active	O
treatment	O
.	O

Table	O
1	O
Su	O
##mma	X
##ry	X
of	O
anal	O
##ges	X
##ic	X
efficacy	O
results	O
Number	O
of	O
patients	B-species
with	O
at	O
least	O
50	O
%	O
pain	O
relief	O
Active	O
treatment	O
and	O
dose	O
(	O
mg	O
)	O
Number	O
of	O
trials	O
Na	O
##p	X
##ro	X
##xen	X
Place	O
##bo	X
Re	O
##lative	X
benefit	O
(	O
95	O
%	O
C	O
##I	X
)	O
N	O
##NT	X
(	O
95	O
%	O
C	O
##I	X
)	O
Na	O
##p	X
##ro	X
##xen	X
sodium	O
550	O
6	O
127	O
/	X
252	X
30	O
/	X
248	X
4	O
.	X
2	X
(	O
2	O
.	X
9	X
to	O
6	O
.	X
0	X
)	O
2	O
.	X
6	X
(	O
2	O
.	X
2	X
to	O
3	O
.	X
2	X
)	O
Na	O
##p	X
##ro	X
##xen	X
sodium	O
/	X
nap	X
##ro	X
##xen	X
440	O
/	X
400	X
3	O
103	O
/	X
210	X
14	O
/	X
124	X
4	O
.	X
8	X
(	O
2	O
.	X
8	X
to	O
8	O
.	X
3	X
)	O
2	O
.	X
7	X
(	O
2	O
.	X
2	X
to	O
3	O
.	X
5	X
)	O
Na	O
##p	X
##ro	X
##xen	X
sodium	O
/	X
nap	X
##ro	X
##xen	X
220	O
/	X
200	X
2	O
54	O
/	X
120	X
13	O
/	X
82	X
2	O
.	X
9	X
(	O
1	O
.	X
6	X
to	O
5	O
.	X
1	X
)	O
3	O
.	X
4	X
(	O
2	O
.	X
4	X
to	O
5	O
.	X
8	X
)	O
Na	O
##p	X
##ro	X
##xen	X
sodium	O
550	O
mg	O
v	O
place	O
##bo	X
In	O
six	O
trials	O
containing	O
500	O
patients	B-species
,	O
252	O
received	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
and	O
248	O
received	O
place	O
##bo	X
.	O

The	O
mean	O
response	O
rate	O
(	O
percentage	O
of	O
patients	B-species
with	O
at	O
least	O
50	O
%	O
pain	O
relief	O
)	O
for	O
nap	O
##ro	X
##xen	X
sodium	O
was	O
50	O
%	O
(	O
127	O
patients	B-species
out	O
of	O
252	O
)	O
,	O
ranging	O
from	O
30	O
%	O
to	O
72	O
%	O
in	O
individual	O
trials	O
(	O
Figure	O
1	O
)	O
.	O

The	O
mean	O
place	O
##bo	X
response	O
rate	O
was	O
12	O
%	O
(	O
30	O
patients	B-species
out	O
of	O
248	O
)	O
,	O
ranging	O
from	O
6	O
%	O
to	O
19	O
%	O
.	O

Figure	O
1	O
L	O
'	X
A	X
##bb	X
##é	X
plot	O
.	O

Per	O
##cent	X
##age	X
of	O
patients	B-species
with	O
at	O
least	O
50	O
%	O
pain	O
relief	O
in	O
place	O
##bo	X
controlled	O
clinical	O
trials	O
of	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
.	X
Each	O
circle	O
represents	O
one	O
included	O
trial	O
.	O

Na	O
##p	X
##ro	X
##xen	X
sodium	O
550	O
mg	O
was	O
significantly	O
better	O
than	O
place	O
##bo	X
with	O
relative	O
benefit	O
4	O
.	X
2	X
(	O
2	O
.	X
9	X
to	O
6	O
.	X
0	X
)	O
.	O

The	O
N	O
##NT	X
was	O
2	O
.	X
6	X
(	O
2	O
.	X
2	X
to	O
3	O
.	X
2	X
)	O
for	O
at	O
least	O
50	O
%	O
pain	O
relief	O
over	O
six	O
hours	O
in	O
post	O
##oper	X
##ative	X
pain	O
of	O
moderate	O
to	O
severe	O
intensity	O
.	O

Na	O
##p	X
##ro	X
##xen	X
/	X
nap	X
##ro	X
##xen	X
sodium	O
400	O
/	X
440	X
mg	O
v	O
place	O
##bo	X
In	O
three	O
trials	O
containing	O
33	O
##4	X
patients	B-species
,	O
210	O
received	O
active	O
treatment	O
and	O
124	O
received	O
place	O
##bo	X
.	O

Thirty	O
-	X
seven	X
of	O
those	O
patients	B-species
on	O
active	O
treatment	O
were	O
given	O
nap	O
##ro	X
##xen	X
400	O
mg	O
.	O

The	O
mean	O
active	O
response	O
rate	O
was	O
49	O
%	O
(	O
103	O
out	O
of	O
210	O
patients	B-species
)	O
,	O
ranging	O
from	O
46	O
%	O
to	O
53	O
%	O
in	O
individual	O
trials	O
.	O

The	O
mean	O
place	O
##bo	X
response	O
rate	O
was	O
11	O
%	O
(	O
14	O
out	O
of	O
124	O
patients	B-species
)	O
,	O
ranging	O
from	O
5	O
%	O
to	O
23	O
%	O
.	O

Active	O
treatment	O
was	O
significantly	O
better	O
than	O
place	O
##bo	X
with	O
relative	O
benefit	O
4	O
.	X
8	X
(	O
2	O
.	X
8	X
to	O
8	O
.	X
3	X
)	O
.	O

The	O
N	O
##NT	X
was	O
2	O
.	X
7	X
(	O
2	O
.	X
2	X
to	O
3	O
.	X
5	X
)	O
for	O
at	O
least	O
50	O
%	O
pain	O
relief	O
over	O
six	O
hours	O
in	O
post	O
##oper	X
##ative	X
pain	O
of	O
moderate	O
to	O
severe	O
intensity	O
.	O

Sen	O
##si	X
##ti	X
##vity	X
analysis	O
showed	O
no	O
significant	O
difference	O
between	O
N	O
##NT	X
##s	X
for	O
nap	O
##ro	X
##xen	X
sodium	O
440	O
mg	O
and	O
nap	O
##ro	X
##xen	X
400	O
mg	O
.	O

Na	O
##p	X
##ro	X
##xen	X
/	X
nap	X
##ro	X
##xen	X
sodium	O
200	O
/	X
220	X
mg	O
v	O
place	O
##bo	X
In	O
two	O
trials	O
containing	O
202	O
patients	B-species
,	O
120	O
received	O
active	O
treatment	O
and	O
82	O
received	O
place	O
##bo	X
.	O

Forty	O
of	O
those	O
patients	B-species
on	O
active	O
treatment	O
were	O
given	O
nap	O
##ro	X
##xen	X
200	O
mg	O
.	O

The	O
mean	O
active	O
response	O
rate	O
was	O
45	O
%	O
(	O
54	O
out	O
of	O
120	O
patients	B-species
)	O
,	O
ranging	O
from	O
30	O
%	O
to	O
53	O
%	O
in	O
individual	O
trials	O
.	O

The	O
mean	O
place	O
##bo	X
response	O
rate	O
was	O
16	O
%	O
(	O
13	O
out	O
of	O
82	O
patients	B-species
)	O
,	O
ranging	O
from	O
10	O
%	O
to	O
23	O
%	O
.	O

Active	O
treatment	O
was	O
significantly	O
better	O
than	O
place	O
##bo	X
with	O
relative	O
benefit	O
2	O
.	X
9	X
(	O
1	O
.	X
6	X
to	O
5	O
.	X
1	X
)	O
.	O

The	O
N	O
##NT	X
was	O
3	O
.	X
4	X
(	O
2	O
.	X
4	X
to	O
5	O
.	X
8	X
)	O
for	O
at	O
least	O
50	O
%	O
pain	O
relief	O
over	O
six	O
hours	O
in	O
post	O
##oper	X
##ative	X
pain	O
of	O
moderate	O
to	O
severe	O
intensity	O
.	O

The	O
N	O
##NT	X
##s	X
for	O
nap	O
##ro	X
##xen	X
200	O
mg	O
(	O
2	O
.	X
3	X
;	O
1	O
.	X
8	X
to	O
3	O
.	X
5	X
)	O
and	O
nap	O
##ro	X
##xen	X
sodium	O
220	O
mg	O
(	O
13	O
;	O
3	O
.	X
7	X
to	O
no	O
benefit	O
)	O
were	O
different	O
in	O
two	O
trials	O
with	O
122	O
and	O
80	O
patients	B-species
respectively	O
.	O

Ad	O
##verse	X
events	O
and	O
withdrawal	O
##s	X
Eight	O
included	O
studies	O
reported	O
adverse	O
events	O
for	O
single	O
dose	O
data	O
[	O
36	O
–	X
40	X
,	O
unpublished	O
studies	O
]	O
.	O

Only	O
five	O
trials	O
using	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
contained	O
sufficient	O
e	O
##val	X
##ua	X
##ble	X
data	O
to	O
pool	O
results	O
[	O
36	O
–	O
38	X
,	O
unpublished	O
studies	O
additional	O
file	O
3	O
]	O
.	O

Forty	O
-	X
seven	X
out	O
of	O
197	O
patients	B-species
(	O
24	O
%	O
)	O
given	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
reported	O
at	O
least	O
one	O
adverse	O
event	O
.	O

Fifty	O
-	X
two	X
out	O
of	O
195	O
patients	B-species
(	O
27	O
%	O
)	O
given	O
place	O
##bo	X
reported	O
at	O
least	O
one	O
adverse	O
event	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
treatment	O
and	O
place	O
##bo	X
,	O
relative	O
risk	O
0	O
.	X
89	X
(	O
0	O
.	X
6	X
to	O
1	O
.	X
3	X
)	O
.	O

One	O
patient	B-species
given	O
nap	O
##ro	X
##xen	X
sodium	O
440	O
mg	O
had	O
severe	O
vomit	O
##ing	X
[	O
1	O
]	O
.	O

In	O
another	O
trial	O
,	O
seven	O
adverse	O
events	O
were	O
`	O
`	X
serious	O
'	O
'	X
in	O
patients	B-species
receiving	O
nap	O
##ro	X
##xen	X
sodium	O
220	O
mg	O
[	O
39	O
]	O
.	O

In	O
##ves	X
##ti	X
##gat	X
##ors	X
in	O
both	O
trials	O
did	O
not	O
regard	O
these	O
events	O
as	O
being	O
related	O
to	O
the	O
study	O
medication	O
.	O

Pat	B-species
##ient	X
withdrawal	O
##s	X
and	O
exclusion	O
##s	X
were	O
not	O
reported	O
consistently	O
.	O

Trials	O
often	O
reported	O
the	O
total	O
number	O
of	O
exclusion	O
##s	X
or	O
withdrawal	O
##s	X
without	O
stating	O
which	O
treatment	O
groups	O
these	O
referred	O
to	O
.	O

Neither	O
was	O
it	O
clear	O
exactly	O
when	O
withdrawal	O
##s	X
occurred	O
,	O
i	O
##e	X
,	O
before	O
assessment	O
of	O
anal	O
##ges	X
##ia	X
at	O
4	O
–	X
6	X
hours	O
,	O
of	O
at	O
some	O
other	O
point	O
before	O
the	O
end	O
of	O
the	O
trial	O
.	O

Four	O
trials	O
did	O
not	O
give	O
specific	O
information	O
for	O
the	O
number	O
of	O
exclusion	O
##s	X
and	O
patient	B-species
withdrawal	O
##s	X
for	O
a	O
single	O
dose	O
of	O
nap	O
##ro	X
##xen	X
/	X
nap	X
##ro	X
##xen	X
sodium	O
[	O
37	O
,	O
41	O
,	O
unpublished	O
studies	O
]	O
.	O

Of	O
the	O
remaining	O
six	O
trials	O
,	O
45	O
out	O
of	O
35	O
##4	X
patients	B-species
assigned	O
to	O
treatment	O
with	O
nap	O
##ro	X
##xen	X
sodium	O
were	O
reported	O
to	O
have	O
withdrawn	O
or	O
been	O
excluded	O
.	O

The	O
majority	O
of	O
these	O
(	O
40	O
/	X
81	X
)	O
were	O
in	O
one	O
trial	O
using	O
nap	O
##ro	X
##xen	X
sodium	O
220	O
mg	O
[	O
39	O
]	O
in	O
which	O
the	O
reasons	O
for	O
disco	O
##ntin	X
##uation	X
were	O
not	O
stated	O
.	O

Ad	O
##verse	X
event	O
related	O
withdrawal	O
##s	X
for	O
nap	O
##ro	X
##xen	X
/	X
nap	X
##ro	X
##xen	X
sodium	O
were	O
clearly	O
reported	O
in	O
three	O
trials	O
.	O

These	O
were	O
one	O
report	O
of	O
post	O
##oper	X
##ative	X
vomit	O
##ing	X
[	O
1	O
]	O
,	O
one	O
report	O
of	O
a	O
headache	B-disease
(	O
not	O
deemed	O
due	O
to	O
study	O
medication	O
by	O
the	O
investigator	O
)	O
[	O
40	O
]	O
,	O
and	O
Re	O
##ici	X
##n	X
et	O
al	O
.	O

[	O
42	O
]	O
reported	O
that	O
two	O
patients	B-species
out	O
of	O
55	O
on	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
and	O
three	O
patients	B-species
out	O
of	O
53	O
on	O
place	O
##bo	X
withdrew	O
due	O
to	O
a	O
clinical	O
##ly	X
relevant	O
adverse	O
event	O
on	O
day	O
one	O
of	O
the	O
study	O
.	O

Re	O
##med	X
##ica	X
##tion	X
Re	O
##med	X
##ica	X
##tion	X
data	O
were	O
pool	O
##ed	X
from	O
four	O
trials	O
[	O
37	O
,	O
42	O
,	O
unpublished	O
studies	O
]	O
to	O
give	O
the	O
percentage	O
re	O
##med	X
##ica	X
##ting	X
by	O
12	O
hours	O
,	O
weighted	O
by	O
the	O
number	O
of	O
patients	B-species
.	O

This	O
was	O
63	O
%	O
(	O
114	O
out	O
of	O
181	O
patients	B-species
)	O
for	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
and	O
78	O
%	O
(	O
140	O
out	O
of	O
180	O
patients	B-species
)	O
for	O
place	O
##bo	X
.	O

Results	O
from	O
five	O
trials	O
[	O
37	O
,	O
38	O
,	O
42	O
,	O
unpublished	O
studies	O
]	O
were	O
pool	O
##ed	X
to	O
give	O
the	O
mean	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
,	O
weighted	O
by	O
the	O
number	O
of	O
patients	B-species
(	O
Figure	O
2	O
)	O
.	O

For	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
this	O
was	O
7	O
.	X
6	X
h	O
##rs	X
(	O
206	O
patients	B-species
)	O
,	O
and	O
for	O
place	O
##bo	X
it	O
was	O
2	O
.	X
6	X
hours	O
(	O
205	O
patients	B-species
)	O
.	O

Figure	O
2	O
Mean	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
.	O

Mean	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
(	O
hours	O
)	O
for	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
and	O
place	O
##bo	X
in	O
post	O
##oper	X
##ative	X
pain	O
,	O
compared	O
with	O
information	O
on	O
place	O
##bo	X
,	O
i	O
##bu	X
##p	X
##ro	X
##fen	X
400	O
mg	O
and	O
r	O
##of	X
##ec	X
##ox	X
##ib	X
50	O
mg	O
[	O
46	O
]	O
.	O

Disc	O
##uss	X
##ion	X
A	O
single	O
oral	O
dose	O
of	O
550	O
mg	O
nap	O
##ro	X
##xen	X
sodium	O
has	O
an	O
N	O
##NT	X
of	O
2	O
.	X
6	X
(	O
2	O
.	X
2	X
to	O
3	O
.	X
2	X
)	O
for	O
at	O
least	O
50	O
%	O
pain	O
relief	O
over	O
six	O
hours	O
in	O
post	O
##oper	X
##ative	X
pain	O
of	O
moderate	O
to	O
severe	O
intensity	O
,	O
compared	O
with	O
place	O
##bo	X
.	O

This	O
means	O
that	O
for	O
approximately	O
every	O
three	O
patients	B-species
given	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
,	O
one	O
would	O
achieve	O
at	O
least	O
a	O
50	O
%	O
reduction	O
in	O
post	O
##oper	X
##ative	X
pain	O
of	O
moderate	O
to	O
severe	O
intensity	O
who	O
would	O
not	O
have	O
done	O
so	O
if	O
given	O
place	O
##bo	X
.	O

The	O
most	O
robust	O
result	O
was	O
for	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
.	O

This	O
analysis	O
contained	O
the	O
most	O
patients	B-species
and	O
is	O
the	O
most	O
clinical	O
##ly	X
relevant	O
because	O
this	O
is	O
the	O
dose	O
commonly	O
used	O
.	O

For	O
a	O
single	O
oral	O
dose	O
of	O
nap	O
##ro	X
##xen	X
/	X
nap	X
##ro	X
##xen	X
sodium	O
400	O
/	X
440	X
mg	O
the	O
N	O
##NT	X
was	O
2	O
.	X
7	X
(	O
2	O
.	X
2	X
to	O
3	O
.	X
5	X
)	O
.	O

For	O
200	O
/	X
220	X
mg	O
,	O
the	O
N	O
##NT	X
was	O
3	O
.	X
4	X
(	O
2	O
.	X
4	X
to	O
5	O
.	X
8	X
)	O
.	O

Do	O
##ses	X
of	O
less	O
than	O
500	O
mg	O
of	O
nap	O
##ro	X
##xen	X
are	O
not	O
commonly	O
used	O
for	O
acute	O
post	O
##oper	X
##ative	X
pain	O
in	O
clinical	O
practice	O
and	O
are	O
therefore	O
of	O
limited	O
clinical	O
value	O
.	O

The	O
results	O
for	O
nap	O
##ro	X
##xen	X
/	X
nap	X
##ro	X
##xen	X
sodium	O
200	O
/	X
220	X
mg	O
and	O
400	O
/	X
440	X
mg	O
are	O
also	O
less	O
reliable	O
than	O
for	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
,	O
because	O
these	O
analyses	O
contained	O
fewer	O
trials	O
and	O
fewer	O
patients	B-species
.	O

Co	O
##mb	X
##ining	X
studies	O
into	O
a	O
meta	O
-	X
analysis	X
may	O
be	O
better	O
than	O
relying	O
on	O
the	O
results	O
from	O
a	O
single	O
small	O
trial	O
,	O
but	O
meta	O
-	X
analysis	X
based	O
on	O
limited	O
data	O
may	O
still	O
not	O
overcome	O
chance	O
effects	O
[	O
17	O
]	O
.	O

N	O
##NT	X
##s	X
for	O
550	O
mg	O
,	O
400	O
/	X
440	X
mg	O
and	O
200	O
/	X
220	X
mg	O
were	O
similar	O
,	O
but	O
there	O
was	O
insufficient	O
information	O
from	O
trials	O
using	O
440	O
mg	O
doses	O
or	O
less	O
to	O
comment	O
on	O
dose	O
response	O
.	O

No	O
increased	O
effect	O
with	O
increased	O
dose	O
was	O
found	O
,	O
but	O
on	O
the	O
limited	O
information	O
available	O
it	O
is	O
not	O
possible	O
to	O
know	O
whether	O
there	O
is	O
no	O
response	O
or	O
whether	O
any	O
response	O
is	O
shallow	O
or	O
has	O
been	O
missed	O
.	O

The	O
relative	O
efficacy	O
of	O
over	O
50	O
anal	O
##ges	X
##ics	X
in	O
acute	O
post	O
##oper	X
##ative	X
pain	O
has	O
been	O
compiled	O
Published	O
versions	O
can	O
be	O
found	O
in	O
Edwards	O
[	O
43	O
]	O
,	O
Collins	O
[	O
44	O
]	O
and	O
Moore	O
[	O
45	O
]	O
.	O

The	O
number	O
of	O
patients	B-species
in	O
each	O
meta	O
-	X
analysis	X
from	O
which	O
N	O
##NT	X
##s	X
have	O
been	O
derived	O
varies	O
considerably	O
,	O
and	O
should	O
be	O
taken	O
into	O
account	O
when	O
comparing	O
N	O
##NT	X
##s	X
.	O

A	O
low	O
N	O
##NT	X
with	O
a	O
narrow	O
confidence	O
interval	O
suggests	O
greater	O
efficacy	O
,	O
and	O
the	O
greater	O
the	O
number	O
of	O
patients	B-species
in	O
the	O
meta	O
-	X
analysis	X
the	O
more	O
robust	O
the	O
N	O
##NT	X
.	O

An	O
N	O
##NT	X
of	O
2	O
.	X
6	X
for	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
is	O
slightly	O
higher	O
(	O
worse	O
)	O
than	O
i	O
##bu	X
##p	X
##ro	X
##fen	X
400	O
mg	O
(	O
2	O
.	X
4	X
;	O
2	O
.	X
3	X
to	O
2	O
.	X
6	X
)	O
,	O
but	O
lower	O
(	O
better	O
)	O
than	O
para	O
##ce	X
##tam	X
##ol	X
1000	O
mg	O
(	O
3	O
.	X
8	X
;	O
3	O
.	X
4	X
to	O
4	O
.	X
4	X
)	O
and	O
in	O
##tra	X
##mus	X
##cular	X
m	O
##or	X
##phine	X
10	O
mg	O
(	O
2	O
.	X
9	X
;	O
2	O
.	X
6	X
to	O
3	O
.	X
6	X
)	O
.	O

This	O
meta	O
-	X
analysis	X
did	O
not	O
compare	O
nap	O
##ro	X
##xen	X
/	X
nap	X
##ro	X
##xen	X
sodium	O
directly	O
with	O
other	O
anal	O
##ges	X
##ics	X
.	O

However	O
,	O
indirect	O
comparisons	O
such	O
as	O
these	O
are	O
still	O
valid	O
.	O

A	O
recent	O
study	O
of	O
44	O
meta	O
-	X
analyses	X
has	O
shown	O
that	O
in	O
most	O
cases	O
,	O
results	O
of	O
adjusted	O
indirect	O
comparisons	O
are	O
not	O
significantly	O
different	O
from	O
those	O
of	O
direct	O
comparisons	O
,	O
with	O
validity	O
of	O
indirect	O
comparisons	O
depending	O
on	O
the	O
internal	O
validity	O
and	O
similarity	O
of	O
the	O
individual	O
trials	O
[	O
16	O
]	O
.	O

The	O
mean	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
for	O
nap	O
##ro	X
##xen	X
sodium	O
550	O
mg	O
was	O
7	O
.	X
6	X
hours	O
(	O
Figure	O
2	O
)	O
.	O

This	O
is	O
similar	O
to	O
that	O
of	O
i	O
##bu	X
##p	X
##ro	X
##fen	X
400	O
mg	O
at	O
7	O
.	X
4	X
hours	O
,	O
but	O
shorter	O
than	O
for	O
co	O
##x	X
-	X
2	X
selective	O
inhibitor	O
##s	X
like	O
r	O
##of	X
##ec	X
##ox	X
##ib	X
50	O
mg	O
,	O
at	O
13	O
.	X
6	X
hours	O
,	O
in	O
mainly	O
dental	O
pain	O
trials	O
[	O
46	O
]	O
.	O

Re	O
##med	X
##ica	X
##tion	X
in	O
trials	O
is	O
a	O
useful	O
marker	O
for	O
determining	O
how	O
long	O
adequate	O
anal	O
##ges	X
##ia	X
lasts	O
.	O

The	O
major	O
efficacy	O
outcomes	O
were	O
total	O
pain	O
relief	O
over	O
4	O
–	X
6	X
hours	O
(	O
TO	O
##TP	X
##AR	X
)	O
,	O
and	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
in	O
trials	O
conducted	O
after	O
third	O
m	O
##olar	X
extraction	O
and	O
after	O
other	O
types	O
of	O
surgery	O
.	O

Seven	O
of	O
10	O
trials	O
giving	O
pain	O
relief	O
data	O
,	O
and	O
three	O
of	O
four	O
giving	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
,	O
were	O
performed	O
in	O
third	O
m	O
##olar	X
extraction	O
studies	O
.	O

Analysis	O
has	O
shown	O
that	O
N	O
##NT	X
##s	X
calculated	O
for	O
the	O
outcome	O
of	O
half	O
pain	O
relief	O
over	O
4	O
–	X
6	X
hours	O
are	O
the	O
same	O
in	O
both	O
these	O
surgical	O
categories	O
,	O
in	O
circumstances	O
where	O
oral	O
anal	O
##ges	X
##ics	X
were	O
appropriate	O
[	O
47	O
]	O
.	O

Whether	O
time	O
to	O
re	O
##med	X
##ica	X
##tion	X
is	O
similar	O
after	O
dental	O
extraction	O
and	O
other	O
post	O
##oper	X
##ative	X
circumstances	O
is	O
not	O
yet	O
known	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
number	O
of	O
patients	B-species
reporting	O
any	O
adverse	O
event	O
for	O
nap	O
##ro	X
##xen	X
/	X
nap	X
##ro	X
##xen	X
sodium	O
compared	O
with	O
place	O
##bo	X
.	O

Trials	O
reporting	O
them	O
did	O
so	O
less	O
rigorous	O
##ly	X
than	O
for	O
efficacy	O
data	O
and	O
the	O
methodology	O
for	O
reporting	O
adverse	O
events	O
varied	O
between	O
studies	O
.	O

This	O
is	O
not	O
unusual	O
for	O
adverse	O
event	O
reporting	O
in	O
acute	O
pain	O
studies	O
[	O
48	O
]	O
.	O

With	O
##dra	X
##wal	X
##s	X
and	O
exclusion	O
##s	X
were	O
reported	O
even	O
less	O
well	O
than	O
adverse	O
events	O
.	O

Con	O
##c	X
##lusion	X
##s	X
Na	O
##p	X
##ro	X
##xen	X
sodium	O
550	O
mg	O
is	O
an	O
effective	O
anal	O
##ges	X
##ic	X
in	O
adults	O
with	O
acute	O
,	O
moderate	O
to	O
severe	O
post	O
##oper	X
##ative	X
pain	O
.	O

Its	O
N	O
##NT	X
compares	O
favour	O
##ably	X
with	O
other	O
anal	O
##ges	X
##ics	X
.	O

A	O
low	O
incidence	O
of	O
adverse	O
events	O
was	O
found	O
but	O
these	O
were	O
poorly	O
reported	O
.	O

Better	O
reporting	O
of	O
information	O
in	O
trials	O
,	O
particularly	O
for	O
adverse	O
events	O
,	O
withdrawal	O
##s	X
and	O
exclusion	O
##s	X
,	O
is	O
required	O
.	O

Co	O
##mp	X
##eting	X
interests	O
RAM	O
has	O
been	O
a	O
consultant	O
for	O
MS	O
##D	X
.	O

RAM	O
&	O
H	O
##J	X
##M	X
have	O
consulted	O
for	O
various	O
pharmaceutical	O
companies	O
.	O

RAM	O
,	O
H	O
##J	X
##M	X
&	O
J	O
##E	X
have	O
received	O
lecture	O
fees	O
from	O
pharmaceutical	O
companies	O
related	O
to	O
anal	O
##ges	X
##ics	X
and	O
other	O
healthcare	O
interventions	O
.	O

All	O
authors	O
have	O
received	O
research	O
support	O
from	O
charities	O
,	O
government	O
and	O
industry	O
sources	O
at	O
various	O
times	O
,	O
but	O
no	O
such	O
support	O
was	O
received	O
for	O
this	O
work	O
.	O

No	O
author	O
has	O
any	O
direct	O
stock	O
holding	O
in	O
any	O
pharmaceutical	O
company	O
.	O

Author	O
##s	X
'	O
contributions	O
L	O
##M	X
was	O
involved	O
with	O
searching	O
,	O
data	O
extraction	O
,	O
quality	O
scoring	O
,	O
analysis	O
and	O
writing	O
.	O

J	O
##E	X
was	O
involved	O
with	O
searching	O
,	O
data	O
extraction	O
,	O
analysis	O
,	O
quality	O
scoring	O
and	O
writing	O
.	O

H	O
##J	X
##M	X
was	O
involved	O
in	O
writing	O
.	O

RAM	O
was	O
involved	O
in	O
data	O
extraction	O
,	O
analysis	O
and	O
writing	O
.	O

Pre	O
-	X
publication	X
history	O
The	O
pre	O
-	X
publication	X
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
Su	O
##pp	X
##lement	X
##ary	X
Material	O
Additional	O
File	O
1	O
Search	O
strategy	O
C	O
##lick	X
here	O
for	O
file	O
Additional	O
File	O
2	O
Ex	O
##cluded	X
studies	O
C	O
##lick	X
here	O
for	O
file	O
Additional	O
File	O
3	O
Table	O
of	O
included	O
studies	O
C	O
##lick	X
here	O
for	O
file	O
E	O
##ff	X
##ica	X
##cy	X
and	O
safety	O
of	O
nap	O
##ro	X
##xen	X
sodium	O
and	O
i	O
##bu	X
##p	X
##ro	X
##fen	X
for	O
pain	O
relief	O
after	O
oral	O
surgery	O
Ana	O
##lge	X
##si	X
##cs	X
Anti	O
-	X
inflammatory	X
Drugs	O
and	O
Anti	O
##py	X
##ret	X
##ics	X
The	O
clinical	O
effect	O
of	O
nap	O
##ro	X
##xen	X
sodium	O
after	O
art	O
##hr	X
##os	X
##copy	X
of	O
the	O
knee	O
:	O
a	O
random	O
##ised	X
,	O
double	O
blind	O
,	O
prospective	O
study	O
T	O
##ia	X
##p	X
##ro	X
##fen	X
##ic	X
acid	O
in	O
the	O
acute	O
treatment	O
of	O
posts	O
##urg	X
##ical	X
pain	O
in	O
den	O
##tist	X
##ry	X
A	O
##cute	X
pain	O
management	O
.	O

Programs	O
in	O
US	O
hospitals	O
and	O
experiences	O
and	O
attitudes	O
among	O
US	O
adults	O
National	O
survey	O
of	O
hospital	O
patients	O
Effect	O
##ive	X
##ness	X
of	O
acute	O
post	O
##oper	X
##ative	X
pain	O
management	O
:	O
I	O
.	O

Evidence	O
from	O
published	O
data	O
Pre	O
##scription	X
Co	O
##st	X
Analysis	O
Non	O
-	X
s	X
##tero	X
##idal	X
anti	O
-	X
inflammatory	X
drugs	O
E	O
##pid	X
##em	X
##iol	X
##og	X
##ic	X
assessment	O
of	O
the	O
safety	O
of	O
conventional	O
non	O
##ster	X
##oid	X
##al	X
anti	O
-	X
inflammatory	X
drugs	O
The	O
safety	O
of	O
NSA	O
##ID	X
##s	X
and	O
related	O
drugs	O
for	O
the	O
management	O
of	O
acute	O
pain	B-disease
:	O
ma	O
##xi	X
##mis	X
##ing	X
benefits	O
and	O
mini	O
##mis	X
##ing	X
risks	O
Non	O
##ster	X
##oid	X
##al	X
anti	O
-	X
inflammatory	X
drug	O
use	O
and	O
acute	B-disease
my	I-disease
##oc	X
##ard	X
##ial	X
in	I-disease
##far	X
##ction	X
Association	O
between	O
nap	O
##ro	X
##xen	X
use	O
and	O
protection	O
against	O
acute	B-disease
my	I-disease
##oc	X
##ard	X
##ial	X
in	I-disease
##far	X
##ction	X
Lower	O
risk	O
of	O
th	O
##rom	X
##boe	X
##mbo	X
##lic	X
card	O
##iovascular	X
events	O
with	O
nap	O
##ro	X
##xen	X
among	O
patients	B-species
with	O
r	B-disease
##he	X
##uma	X
##to	X
##id	X
art	I-disease
##hr	X
##itis	X
Co	O
##mb	X
##ining	X
data	O
and	O
Inter	O
##p	X
##ret	X
##ing	X
the	O
Results	O
Val	O
##id	X
##ity	X
of	O
indirect	O
comparisons	O
for	O
est	O
##imating	X
efficacy	O
of	O
competing	O
interventions	O
:	O
empirical	O
evidence	O
from	O
published	O
meta	O
-	X
analyses	X
Si	O
##ze	X
is	O
everything	O
-	O
large	O
amounts	O
of	O
information	O
are	O
needed	O
to	O
overcome	O
random	O
effects	O
in	O
est	O
##imating	X
direction	O
and	O
magnitude	O
of	O
treatment	O
effects	O
Evolution	O
of	O
treatment	O
effects	O
over	O
time	O
:	O
Em	O
##pi	X
##rical	X
In	O
##sight	X
From	O
re	O
##cu	X
##rs	X
##ive	X
cumulative	O
meta	O
-	X
analyses	X
Five	O
Easy	O
pieces	O
on	O
evidence	O
based	O
medicine	O
(	O
2	O
)	O
I	O
##mp	X
##roving	X
the	O
quality	O
of	O
meta	O
-	X
analyses	X
of	O
random	O
##ised	X
controlled	O
trials	O
:	O
the	O
Q	O
##U	X
##OR	X
##OM	X
statement	O
Dev	O
##elo	X
##ping	X
a	O
database	O
of	O
published	O
reports	O
of	O
random	O
##ised	X
clinical	O
trials	O
in	O
pain	O
research	O
As	O
##ses	X
##sing	X
the	O
quality	O
of	O
reports	O
of	O
random	O
##ised	X
clinical	O
trials	O
:	O
is	O
blinding	O
necessary	O
?	O

Der	O
##iving	X
di	O
##cho	X
##tom	X
##ous	X
outcome	O
measures	O
from	O
continuous	O
data	O
in	O
random	O
##ised	X
controlled	O
trials	O
of	O
anal	O
##ges	X
##ics	X
:	O
Der	O
##iving	X
di	O
##cho	X
##tom	X
##ous	X
outcome	O
measures	O
from	O
continuous	O
data	O
in	O
random	O
##ised	X
controlled	O
trials	O
of	O
anal	O
##ges	X
##ics	X
:	O
Use	O
of	O
pain	O
intensity	O
and	O
visual	O
analogue	O
scales	O
Der	O
##iving	X
di	O
##cho	X
##tom	X
##ous	X
outcome	O
measures	O
from	O
continuous	O
data	O
in	O
random	O
##ised	X
controlled	O
trials	O
of	O
anal	O
##ges	X
##ics	X
:	O
V	O
##eri	X
##fication	X
from	O
independent	O
data	O
Single	O
-	X
dose	X
anal	O
##ges	X
##ic	X
studies	O
:	O
the	O
upside	O
and	O
down	O
##side	X
of	O
ass	O
##ay	X
sensitivity	O
The	O
number	O
needed	O
to	O
treat	O
:	O
a	O
clinical	O
##ly	X
useful	O
measure	O
of	O
treatment	O
effect	O
Cal	O
##cula	X
##ting	X
confidence	O
intervals	O
for	O
relative	O
risk	O
,	O
odds	O
ratios	O
and	O
standard	O
##ised	X
ratios	O
and	O
rates	O
Met	O
##a	X
-	X
analysis	X
in	O
clinical	O
research	O
An	O
evaluation	O
of	O
ho	O
##mo	X
##gene	X
##ity	X
tests	O
in	O
meta	O
-	X
analyses	X
in	O
pain	O
using	O
simulation	O
##s	X
of	O
individual	O
patient	B-species
data	O
Statistical	O
he	O
##tero	X
##gene	X
##ity	X
in	O
systematic	O
reviews	O
of	O
clinical	O
trials	O
:	O
a	O
critical	O
app	O
##rai	X
##sal	X
of	O
guidelines	O
and	O
practice	O
Mi	O
##sle	X
##ading	X
fun	O
##nel	X
plot	O
for	O
detection	O
of	O
bias	O
in	O
meta	O
-	X
analysis	X
Public	O
##ation	X
and	O
related	O
bias	O
in	O
meta	O
-	X
analysis	X
:	O
power	O
of	O
statistical	O
tests	O
and	O
prevalence	O
in	O
the	O
literature	O
Impact	O
of	O
covert	O
du	O
##plicate	X
publication	O
on	O
meta	O
-	X
analysis	X
:	O
a	O
case	O
study	O
Co	O
##mp	X
##aris	X
##on	X
of	O
the	O
action	O
of	O
3	O
non	O
-	X
s	X
##tero	X
##idal	X
anti	O
-	X
inflammatory	X
agents	O
in	O
the	O
control	O
of	O
post	O
-	X
operative	X
pain	O
B	O
##rom	X
##fen	X
##ac	X
sodium	O
,	O
nap	O
##ro	X
##xen	X
sodium	O
,	O
and	O
k	O
##eto	X
##rol	X
##ac	X
in	O
moderate	O
to	O
severe	O
post	O
##oper	X
##ative	X
pain	O
Ana	O
##lge	X
##si	X
##c	X
effect	O
of	O
nap	O
##ro	X
##xen	X
sodium	O
,	O
code	O
##ine	X
,	O
a	O
nap	O
##ro	X
##xen	X
-	X
code	X
##ine	X
combination	O
and	O
as	O
##pi	X
##rin	X
on	O
the	O
post	O
##oper	X
##ative	X
pain	O
of	O
oral	O
surgery	O
E	O
##ff	X
##ica	X
##cy	X
and	O
to	O
##ler	X
##ability	X
of	O
the	O
specific	O
c	O
##y	X
##c	X
##lo	X
##ox	X
##y	X
##gen	X
##ase	X
-	X
2	X
inhibitor	O
D	O
##FP	X
compared	O
with	O
nap	O
##ro	X
##xen	X
sodium	O
in	O
patients	B-species
with	O
post	O
##oper	X
##ative	X
dental	B-disease
pain	I-disease
A	O
double	O
-	X
blind	X
,	O
random	O
##ized	X
study	O
of	O
nap	O
##ro	X
##xen	X
sodium	O
,	O
i	O
##bu	X
##p	X
##ro	X
##fen	X
,	O
and	O
place	O
##bo	X
in	O
post	O
##oper	X
##ative	X
dental	B-disease
pain	I-disease
A	O
single	O
-	X
dose	X
,	O
double	O
-	X
blind	X
comparison	O
of	O
nap	O
##ro	X
##xen	X
sodium	O
,	O
ace	O
##tam	X
##ino	X
##phe	X
##n	X
,	O
and	O
place	O
##bo	X
in	O
post	O
##oper	X
##ative	X
dental	O
pain	O
As	O
##say	X
of	O
As	O
##pi	X
##rin	X
and	O
nap	O
##ro	X
##xen	X
anal	O
##ges	X
##ia	X
E	O
##ff	X
##ica	X
##cy	X
of	O
single	O
-	X
dose	X
and	O
multi	O
##dos	X
##e	X
r	O
##of	X
##ec	X
##ox	X
##ib	X
in	O
the	O
treatment	O
of	O
post	O
-	X
or	X
##th	X
##oped	X
##ic	X
surgery	O
pain	O
Oral	O
as	O
##pi	X
##rin	X
in	O
post	O
##oper	X
##ative	X
pain	O
:	O
a	O
quantitative	O
systematic	O
review	O
Oral	O
i	O
##bu	X
##p	X
##ro	X
##fen	X
and	O
di	O
##c	X
##lo	X
##fen	X
##ac	X
in	O
post	O
##oper	X
##ative	X
pain	O
:	O
a	O
quantitative	O
systematic	O
review	O
Para	O
##ce	X
##tam	X
##ol	X
with	O
and	O
without	O
code	O
##ine	X
in	O
acute	O
pain	O
:	O
a	O
quantitative	O
systematic	O
review	O
Single	O
-	X
dose	X
r	O
##of	X
##ec	X
##ox	X
##ib	X
for	O
acute	O
post	O
##oper	X
##ative	X

